The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objectives: Many reports demonstrate improvements in cardiovascular risk factors during GH replacement (rhGH) in adult GH deficiency (GHD). However, it remains to be determined to what extent these changes translate into a reduction of increased cardiovascular morbidity and mortality. The aim of this study was to evaluate the effects of long-term rhGH replacement on the prevalence of the metabolic syndrome (MS). Design, settings, main outcome measures: The MS was scored by the National Cholesterol Education Program-Adult Treatment Panel III definition in 50 consecutive GHD patients (45 ± 9 years of age), before and after 2 and 5 years of rhGH replacement, and the data of untreated patients were compared with the general population using data from a Dutch population-based study (n = 1062, 44 ± 8 years of age). Results: Hypertriglyceridaemia (46.0 vs 18.5%, P < 0.0001), hypertension (66.0 vs 35.5%, P < 0.0001) and abdominal obesity (38.0 vs 23.4%, P = 0.0178) were more prevalent in untreated patients when compared with controls, resulting in a higher prevalence of the MS in patients (38.0 vs 15.7%, P < 0.0001). During rhGH replacement at a mean dose of 0.5 ± 0.2 mg/day resulting in IGF-I concentrations in the normal age-adjusted reference range, mean high-density lipoprotein cholesterol level increased compared with baseline (P < 0.001). However, the prevalence of (components of) the MS did not change after 2 or 5 years of treatment with rhGH. Conclusion: In this study, the prevalence of the MS in patients with GHD is increased compared with healthy controls, irrespective of rhGH replacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 1×
“Patients mean maximal GH response during insulin-induced hypoglycaemia was only 0.3G0.4 mg/l (range 0.1‐1.6 mg/l), confirming the diagnosis of severe GHD ( 17 ) (Table 2).”
BackgroundInfluential
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“Human studies have shown that growth hormone (GH) levels or secretion are altered in visceral obese individuals with a high cardiometabolic risk (85, 239, 339, 373, 375, 434, 577, 589, 590, 613).”
BackgroundThe Association Between IGF-I and Insulin Resistance
Friedrich, N., Thuesen, B., Jørgensen, T., Juul, A., Spielhagen, C., Wallaschofksi, H., & Linneberg, A. (2012) · Diabetes Care · doi:10.2337/dc11-1833 · Cited by 283
Attanasio, A. F., Mo, D., Erfurth, E. M., Tan, M., Ho, K. Y., Kleinberg, D., Zimmermann, A. G., & Chanson, P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1326 · Cited by 115
Verhelst, J., Mattsson, A. F., Luger, A., Thunander, M., Góth, M. I., Kołtowska-Häggström, M., & Abs, R. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0599 · Cited by 71
Allo Miguel, G., Serraclara Plá, A., Partida Muñoz, M. L., Martínez Díaz-Guerra, G., & Hawkins, F. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816643908 · Cited by 22
Metadata
- Authors
- van der Klaauw, A. A., Biermasz, N. R., Feskens, E. J. M., Bos, M. B., Smit, J. W. A., Roelfsema, F., Corssmit, E. P. M., Pijl, H., Romijn, J. A., & Pereira, A. M.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-04
- Volume
- 156
- Issue
- 4
- Pages
- 455-462
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2148371797
- Cited by
- 86
- References
- 3
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. https://app.cochat.ai/papers/10.1530/eje-06-0699
- The paper
- van der Klaauw, A. A., Biermasz, N. R., Feskens, E. J. M., Bos, M. B., Smit, J. W. A., Roelfsema, F., Corssmit, E. P. M., Pijl, H., Romijn, J. A., & Pereira, A. M. (2007). The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. European Journal of Endocrinology. https://doi.org/10.1530/eje-06-0699
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.